Forest to pay $164M for various violations

Share this article:
A federal judge has sentenced Forest Pharmaceuticals to pay a criminal fine of $150 million and forfeit $14 million in assets for its guilty plea last November to felony and misdemeanor charges. These involved obstructing an FDA regulatory inspection, distributing Levothroid when it was an unapproved new drug, and illegally promoting Celexa for use in children and adolescents.
The Justice Department says the sentencing was the final component of a global resolution totaling more than $313 million to resolve criminal and civil allegations against Forest.
In September 2010, Forest Laboratories and Forest Pharmaceuticals entered a civil settlement to resolve False Claims Act charges involving Levothroid, Celexa and Lexapro. As part of the civil settlement, Forest agreed to pay over $149 million, including more than $88 million to the federal government and more than $60 million to states.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.